To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

This is a phase 3 double-blind, randomized, placebo-controlled, study to assess the efficacy and safety of Furmonertinib (AST2818) versus placebo in patients with stage II-IIIA non-small cell lung cancer (NSCLC) with centrally confirmed, most common sensitising EGFR mutations (Ex19Del and L858R) either alone or in combination with other EGFR mutations as confirmed by a central test, who have had complete tumour resection, with or without postoperative adjuvant chemotherapy.

NCT Number	NCT04853342
Lead Sponsor	Allist Pharmaceuticals, Inc.
Conditions	Non-small Cell Lung Carcinoma
Enrollment	318 participants
Start Date	2021-06-07
Primary Completion	2026-12 (estimated)
Study Completion	2030-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-13